Anticancer Small-Molecule Agents Targeting Eukaryotic Elongation Factor 1A: State of the Art.

Abstract

Eukaryotic elongation factor 1A (eEF1A) canonically delivers amino acyl tRNA to the ribosomal A site during the elongation stage of protein biosynthesis. Yet paradoxically, the oncogenic nature of this instrumental protein has long been recognized. Consistently, eEF1A has proven to be targeted by a wide assortment of small molecules with excellent anticancer activity, among which plitidepsin has been granted approval for the treatment of multiple myeloma. Meanwhile, metarrestin is currently under clinical development for metastatic cancers. Bearing these exciting advances in mind, it would be desirable to present a systematic up-to-date account of the title topic, which, to the best of our knowledge, has thus far been unavailable in the literature. The present review summarizes recent advances in eEF1A-targeting anticancer agents, both naturally occurring and synthetically crafted, with regard to their discovery or design, target identification, structure-activity relationship, and mode of action. Their structural diversity and differential eEF1A-targeting mechanisms warrant continuing research in pursuit of curing eEF1A-driven malignancy.

• Authors: Han Zhang, Jiayou Cai, Siqi Yu, Bin Sun, Weicheng Zhang
• Journal: International journal of molecular sciences (Int J Mol Sci) Vol. 24 Issue 6 (Mar 08 2023) ISSN: 1422-0067 [Electronic] Switzerland
• PMID: 36982256 (Publication Type: Journal Article, Review)

Chemical References

• Peptide Elongation Factor 1
• Antineoplastic Agents

Topics

• Peptide Elongation Factor 1 (genetics, metabolism)
• Protein Biosynthesis
• Saccharomyces cerevisiae (metabolism)
• Ribosomes (metabolism)
• Antineoplastic Agents (pharmacology, therapeutic use, metabolism)